Anebulo Pharmaceuticals, Inc. Net Income Loss

• Anebulo Pharmaceuticals, Inc. showed a decrease of -3.5% in Net Income Loss from 2024 to 2025.
• This data is from Anebulo Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
• XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 5 years of available data (2021 to 2025), Anebulo Pharmaceuticals, Inc.'s Net Income Loss has grown by 72.0%.
• Historical annual values: Fiscal year 2025: -$8.48 million | Fiscal year 2024: -$8.20 million | Fiscal year 2023: -$11.73 million | Fiscal year 2022: -$6.83 million | Fiscal year 2021: -$30.25 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026